Biocon’s subsidiary in Malaysia, Biocon Sdn. Bhd., has been issued a certificate of GMP Compliance for its Insulin manufacturing facility by the HPRA (Ireland) as the representative European inspection authority. Biocon’s Malaysia facility was inspected by the EMA in April 2017.
The certificate of GMP compliance reflects that the agency considered the site to be in compliance with principles and guidelines of good manufacturing practices for active substances, sterile drug products and quality control testing operations.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
